Published in Genome Res on December 06, 2011
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | NCT00137111
Acute lymphoblastic leukaemia. Lancet (2013) 3.44
The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther (2012) 2.90
Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther (2012) 2.48
OATP1B1 polymorphism as a determinant of erythromycin disposition. Clin Pharmacol Ther (2012) 2.43
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood (2012) 1.90
Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics. Am J Physiol Cell Physiol (2013) 1.56
Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet (2012) 1.41
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol (2015) 1.26
Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res (2012) 1.24
Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood (2012) 1.17
The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther (2014) 1.17
Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med (2013) 1.11
Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era. Clin Pharmacol Ther (2013) 1.10
Inherited genetic variation in childhood acute lymphoblastic leukemia. Blood (2015) 1.09
Relating human genetic variation to variation in drug responses. Trends Genet (2012) 1.05
Haplotype kernel association test as a powerful method to identify chromosomal regions harboring uncommon causal variants. Genet Epidemiol (2013) 1.04
Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset. Hum Mol Genet (2013) 1.00
Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res (2013) 0.97
PGRNseq: a targeted capture sequencing panel for pharmacogenetic research and implementation. Pharmacogenet Genomics (2016) 0.96
A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm. Clin Pharmacol Ther (2013) 0.91
Pharmacogenomics of chemotherapeutic susceptibility and toxicity. Genome Med (2012) 0.89
Pharmacogenomics discovery and implementation in genome-wide association studies era. Wiley Interdiscip Rev Syst Biol Med (2012) 0.88
A comprehensive evaluation of collapsing methods using simulated and real data: excellent annotation of functionality and large sample sizes required. Front Genet (2014) 0.85
Impact of the Interaction between 3'-UTR SNPs and microRNA on the Expression of Human Xenobiotic Metabolism Enzyme and Transporter Genes. Front Genet (2012) 0.84
Genomic architecture of pharmacological efficacy and adverse events. Pharmacogenomics (2014) 0.83
Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. Antimicrob Agents Chemother (2014) 0.83
Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy. Breast Cancer Res Treat (2014) 0.82
Pharmacogenomics in oncology care. Front Genet (2014) 0.82
Multilocus genotypes of relevance for drug metabolizing enzymes and therapy with thiopurines in patients with acute lymphoblastic leukemia. Front Genet (2013) 0.82
Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. Clin Pharmacol Ther (2016) 0.81
Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics. Clin Pharmacokinet (2016) 0.81
The physiological role of drug transporters. Protein Cell (2015) 0.80
Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted? Int J Mol Sci (2015) 0.80
Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet Med (2016) 0.80
DMET™ (Drug Metabolism Enzymes and Transporters): a Pharmacogenomic platform for precision medicine. Oncotarget (2016) 0.80
Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma. Radiol Oncol (2014) 0.80
Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. Blood Rev (2015) 0.79
Expression of mRNA transcripts encoding membrane transporters detected with whole transcriptome sequencing of human brain and liver. Pharmacogenet Genomics (2013) 0.79
Uptake carriers and oncology drug safety. Drug Metab Dispos (2013) 0.79
Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia. Pharmacogenomics J (2014) 0.79
Role of pharmacogenetics in public health and clinical health care: a SWOT analysis. Eur J Hum Genet (2016) 0.79
'Toxgnostics': an unmet need in cancer medicine. Nat Rev Cancer (2014) 0.78
Plasma membrane transporters in modern liver pharmacology. Scientifica (Cairo) (2012) 0.78
Genetic variants in the human SLCO1B1 gene and individual variations in methotrexate clearance. Pharmacogenomics (2012) 0.77
Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis. Drug Metab Dispos (2016) 0.76
Genetic determinants for methotrexate response in juvenile idiopathic arthritis. Front Pharmacol (2015) 0.76
Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance. Br J Clin Pharmacol (2014) 0.75
Interindividual and interethnic variability in drug disposition: <mt > Polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1). Br J Clin Pharmacol (2016) 0.75
SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization. Pharmacogenomics (2015) 0.75
Preventing and Managing Toxicities of High-Dose Methotrexate. Oncologist (2016) 0.75
Pharmacogenomics of adverse effects of anti-leukemic agents in children. J Pediatr Pharmacol Ther (2012) 0.75
Genotypes Affecting the Pharmacokinetics of Anticancer Drugs. Clin Pharmacokinet (2017) 0.75
Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use. Int J Mol Sci (2016) 0.75
More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances. J Clin Pharmacol (2016) 0.75
Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics. Pharmaceuticals (Basel) (2012) 0.75
SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer. PLoS One (2013) 0.75
Highlights from the latest pharmacogenomic genome-wide association studies. Pharmacogenomics (2013) 0.75
Genome Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality. Clin Cancer Res (2017) 0.75
Inference of population structure using multilocus genotype data. Genetics (2000) 147.76
A method and server for predicting damaging missense mutations. Nat Methods (2010) 78.53
A new statistical method for haplotype reconstruction from population data. Am J Hum Genet (2001) 59.30
Predicting deleterious amino acid substitutions. Genome Res (2001) 28.95
A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase. Am J Hum Genet (2006) 28.32
MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol (2010) 26.41
SNPs3D: candidate gene and SNP selection for association studies. BMC Bioinformatics (2006) 21.54
Common and rare variants in multifactorial susceptibility to common diseases. Nat Genet (2008) 13.95
Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. Am J Hum Genet (2011) 8.53
Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc Natl Acad Sci U S A (2006) 8.20
Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet (2010) 7.08
Statistical analysis strategies for association studies involving rare variants. Nat Rev Genet (2010) 6.79
Rare variant association analysis methods for complex traits. Annu Rev Genet (2010) 5.59
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21
Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. Nat Genet (2010) 3.22
Sequence-based prediction of pathological mutations. Proteins (2004) 2.71
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics (2006) 2.66
Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med (1998) 2.59
Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem (2001) 2.42
A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol (2000) 2.21
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol (2009) 2.20
LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology (2001) 2.02
Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther (2007) 1.96
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics (2004) 1.87
Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics (2005) 1.85
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther (2005) 1.74
Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther (2004) 1.67
Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med (1986) 1.67
A genome-wide comparison of the functional properties of rare and common genetic variants in humans. Am J Hum Genet (2011) 1.56
Replication strategies for rare variant complex trait association studies via next-generation sequencing. Am J Hum Genet (2010) 1.51
Global analysis of genetic variation in SLCO1B1. Pharmacogenomics (2008) 1.47
Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos (2004) 1.45
Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest (2010) 1.37
ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence. Leukemia (2010) 1.34
Genetic architecture of ambulatory blood pressure in the general population: insights from cardiovascular gene-centric array. Hypertension (2010) 1.22
Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol (2005) 1.15
Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia. Lancet (1984) 1.10
Pharmacogenetics of drug transporters. Curr Pharm Des (2010) 1.08
Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab Dispos (2008) 1.06
Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer (2011) 1.05
Investigation of inter-individual variability of the one-carbon folate pathway: a bioinformatic and genetic review. Pharmacogenomics J (2009) 1.04
Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics (2004) 1.02
Pharmacogenomics: will the promise be fulfilled? Nat Rev Genet (2010) 0.92
Several conserved positively charged amino acids in OATP1B1 are involved in binding or translocation of different substrates. J Membr Biol (2010) 0.91
MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol (2010) 26.41
Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet (2008) 22.35
Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet (2008) 20.66
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
Evolutionary and biomedical insights from the rhesus macaque genome. Science (2007) 16.21
Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet (2008) 15.94
Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet (2005) 14.09
Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet (2009) 12.44
Genotype, haplotype and copy-number variation in worldwide human populations. Nature (2008) 12.40
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83
Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30
Variants in MTNR1B influence fasting glucose levels. Nat Genet (2008) 10.85
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Large-scale sequence analysis of avian influenza isolates. Science (2006) 9.87
Automating sequence-based detection and genotyping of SNPs from diploid samples. Nat Genet (2006) 9.04
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet (2010) 8.55
The genome sequence of taurine cattle: a window to ruminant biology and evolution. Science (2009) 8.23
Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95
Acute lymphoblastic leukemia. N Engl J Med (2004) 7.83
Genotype-imputation accuracy across worldwide human populations. Am J Hum Genet (2009) 7.28
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fat distribution. PLoS Genet (2009) 5.81
Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A (2003) 5.77
Functional and evolutionary insights from the genomes of three parasitoid Nasonia species. Science (2010) 5.56
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol (2009) 5.22
MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst (2005) 5.22
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89
Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest (2007) 4.47
Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2012) 4.42
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35
The tumor lysis syndrome. N Engl J Med (2011) 4.29
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16
Gene expression profiling of pediatric acute myelogenous leukemia. Blood (2004) 3.77
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol (2010) 3.76
CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature (2011) 3.72
Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet (2009) 3.71
Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation (2011) 3.68
Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med (2003) 3.57
The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2011) 3.40
Bayesian enrichment strategies for randomized discontinuation trials. Biometrics (2011) 3.39
Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol (2008) 3.34
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. J Clin Oncol (2011) 3.05
Moving towards individualized medicine with pharmacogenomics. Nature (2004) 2.99
Pharmacogenomics and individualized drug therapy. Annu Rev Med (2006) 2.95
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res (2012) 2.95
Direct ubiquitination of pattern recognition receptor FLS2 attenuates plant innate immunity. Science (2011) 2.93
Robust estimation of the false discovery rate. Bioinformatics (2006) 2.87
NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol (2010) 2.85
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst (2002) 2.84
Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. J Clin Oncol (2003) 2.83
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood (2012) 2.82